ART352-L

Biologic

AAnkasa Regenerative Therapeutics, Inc.

ART352-L is one of 39 biologic programs targeting Spinal Fusion. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal FusionActive, not recruiting

Spinal FusionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Spinal Fusion

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

MS Contin

HHikma Pharmaceuticals LLC

Approved

4 3

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 4

Marcaine

IInnocoll

Approved

2 5

Toradol

JJavelin Pharmaceuticals

Approved

2 6

Decadron

AAspen Global Incorporated

Approved

2 7

Vancocin

HHikma Pharmaceuticals LLC

Approved

2 8

Vivarin

HHikma Pharmaceuticals LLC

Approved

1 9

Duragesic

CCephalon

Approved

1 10

Xylocaine

MMEDRx USA, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Spinal Fusion1 trial

Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

Unknown status·AAnkasa Regenerative Therapeutics, Inc.·Phase 1/2·NCT04378543·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ART352-L. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ART352-L compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ART352-L. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ankasa Regenerative Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: AAnkasa Regenerative Therapeutics, Inc.

ART352-L

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Spinal Fusion1 trial

References

Drug Info

Quick Facts

Related News